strategy / Interview

‘The Contract farming ordinance is no gamechanger… it will drive adoption to 5%, at best’

The agriculture sector is poorly understood and planned for, so Ajay Jakhar of Bharat Krishak Samaj schools investors 

strategy / Feature

Tata Elxsi is steering away from the automotive lane to remain on the growth track

The overshadowed Tata company is proving its worth with swift and smart detours 

strategy / Feature

MakeMyTrip’s business is badly hit, but that is not the story

The aggregator seems well anchored with a strong cash position and aggressive cost management 

strategy / Feature

Will Glenmark’s COVID-19 drug give it a new lease of life or just a short energy boost?

The pharma major has taken a different path from peers, in launching a new drug instead of inking a licensing deal 

strategy / Feature

Will Thierry Delaporte’s French Connection help Wipro climb up the pecking order?

The tech major has once again sought an “outsider” to lead its turnaround

strategy / Feature

The ride-hailing industry’s drive has come to a screeching halt. Can Ola survive?

Mounting losses, imperfect bets and tough lessons. The taxi company was just about to prove its worth, when the pandemic threw a spanner in

strategy / Feature

United Spirits’ loss is Pernod Ricard’s gain. But no, that’s not the story

New Indian brands have stormed the mid-market whisky segment. Little grains do a mighty ocean make

strategy / Feature

Santoor ke paas ‘Mummy’ hain

With a strong marketing strategy that has connected with consumers over two decades, the soap’s future looks radiant

strategy / Feature

Quickr sand

With its multiple acquisitions, the online-classifieds company bit off more than it could chew

strategy / Feature

How Wipro is shunning risk and chasing innovation

The IT giant’s venture arm has scored big with its conservative strategy 

strategy / Feature

How Truecaller found its true calling in India

How the spam-screening, caller-id app found a wildly successful market in India

strategy / Interview

Biocon's Kiran Mazumdar Shaw's prescription for fighting COVID-19

Biocon CMD shares her insights on how Indian biotech industry can leverage the coronavirus crisis and turn it into a massive opportunity